The assessment of human organic cation transporter 1 (hOCT1)
mRNA expression in patients with chronic myelogenous leukemia
is affected by the proportion of different cells types in the
analyzed cell population

J 2010

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population

RÁČIL, Zdeněk, Filip RÁZGA, Lucie BUREŠOVÁ, Tomáš JURČEK, Dana DVOŘÁKOVÁ et. al.

Basic information

Original name

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population

Authors

RÁČIL, Zdeněk (203 Czech Republic, guarantor, belonging to the institution), Filip RÁZGA (703 Slovakia, belonging to the institution), Lucie BUREŠOVÁ (203 Czech Republic, belonging to the institution), Tomáš JURČEK (203 Czech Republic, belonging to the institution), Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Shira TIMILSINA (203 Czech Republic, belonging to the institution), Petr CETKOVSKÝ (203 Czech Republic) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

American Journal of Hematology, 2010, 0361-8609

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.576

RIV identification code

RIV/00216224:14110/10:00067349

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/ajh.21722

UT WoS

000279506200018

Keywords in English

RESIDUAL DISEASE DETECTION; POLYMERASE-CHAIN-REACTION; CHRONIC MYELOID-LEUKEMIA; CANCER PROGRAM; OCT-1 ACTIVITY; IMATINIB; RESISTANCE; DETERMINANT; EUROPE

Abstract

V originále

The monitoring of hOCT1 mRNA expression in patients with chronic myelogenous leukemia (CML) was used for predicting the response to imatinib treatment. However, different cell populations from patients who received various degrees of pretreatment were used for this analysis. Therefore, several biases in the results and their interpretation may arise. We investigated hOCT1 mRNA expression in different cell populations of peripheral blood (PB) from healthy volunteers and in imatinib nave de novo CML patients by analyzing changes in hOCT1 mRNA expression during the first 6 months of imatinib therapy. The hOCT1 mRNA expression was significantly higher in PB polymorphonuclears compared to mononuclears. The hOCT1 mRNA expression in total PB leukocytes is, therefore, preferentially determined by the percentage of polymorphonuclears. Expression in each analyzed group of cells was always significantly lower in imatinib nave de novo CML patients compared to healthy volunteers. This difference disappeared after the initiation of imatinib therapy, suggesting that CML tumor burden and the degree of pretreatment at the time of monitoring were both influencing factors.

Links

MSM0021622430, plan (intention)

Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies

Citovat

RÁČIL, Zdeněk, Filip RÁZGA, Lucie BUREŠOVÁ, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Shira TIMILSINA, Petr CETKOVSKÝ and Jiří MAYER. The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. American Journal of Hematology. 2010, vol. 85, No 7, p. 525-528. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.21722.

@article{966872,
   author = {Ráčil, Zdeněk and Rázga, Filip and Burešová, Lucie and Jurček, Tomáš and Dvořáková, Dana and Žáčková, Daniela and Timilsina, Shira and Cetkovský, Petr and Mayer, Jiří},
   article_number = {7},
   doi = {http://dx.doi.org/10.1002/ajh.21722},
   keywords = {RESIDUAL DISEASE DETECTION; POLYMERASE-CHAIN-REACTION; CHRONIC MYELOID-LEUKEMIA; CANCER PROGRAM; OCT-1 ACTIVITY; IMATINIB; RESISTANCE; DETERMINANT; EUROPE},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population},
   volume = {85},
   year = {2010}
}

TY  - JOUR
ID  - 966872
AU  - Ráčil, Zdeněk - Rázga, Filip - Burešová, Lucie - Jurček, Tomáš - Dvořáková, Dana - Žáčková, Daniela - Timilsina, Shira - Cetkovský, Petr - Mayer, Jiří
PY  - 2010
TI  - The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population
JF  - American Journal of Hematology
VL  - 85
IS  - 7
SP  - 525-528
EP  - 525-528
SN  - 03618609
KW  - RESIDUAL DISEASE DETECTION
KW  - POLYMERASE-CHAIN-REACTION
KW  - CHRONIC MYELOID-LEUKEMIA
KW  - CANCER PROGRAM
KW  - OCT-1 ACTIVITY
KW  - IMATINIB
KW  - RESISTANCE
KW  - DETERMINANT
KW  - EUROPE
N2  - The monitoring of hOCT1 mRNA expression in patients with chronic myelogenous leukemia (CML) was used for predicting the response to imatinib treatment. However, different cell populations from patients who received various degrees of pretreatment were used for this analysis. Therefore, several biases in the results and their interpretation may arise. We investigated hOCT1 mRNA expression in different cell populations of peripheral blood (PB) from healthy volunteers and in imatinib nave de novo CML patients by analyzing changes in hOCT1 mRNA expression during the first 6 months of imatinib therapy. The hOCT1 mRNA expression was significantly higher in PB polymorphonuclears compared to mononuclears. The hOCT1 mRNA expression in total PB leukocytes is, therefore, preferentially determined by the percentage of polymorphonuclears. Expression in each analyzed group of cells was always significantly lower in imatinib nave de novo CML patients compared to healthy volunteers. This difference disappeared after the initiation of imatinib therapy, suggesting that CML tumor burden and the degree of pretreatment at the time of monitoring were both influencing factors.
ER  -

RÁČIL, Zdeněk, Filip RÁZGA, Lucie BUREŠOVÁ, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Shira TIMILSINA, Petr CETKOVSKÝ and Jiří MAYER. The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. \textit{American Journal of Hematology}. 2010, vol.~85, No~7, p.~525-528. ISSN~0361-8609. Available from: https://dx.doi.org/10.1002/ajh.21722.

Detailed Information on Publication Record